bioAffinity Technologies Publishes Comprehensive Clinical Framework for CyPath® Lung: Key Developments for Investors
Key Highlights from the Report
- Publication of New Clinical Framework: bioAffinity Technologies (Nasdaq: BIAF; BIAFW) has released a comprehensive clinical review and white paper, authored by Chief Medical Officer Dr. Gordon H. Downie, providing a practical framework for integrating its CyPath® Lung test into the evaluation of pulmonary nodules and cancer surveillance.
- Addressing Market Need: The framework addresses the increasing demand for better risk stratification as lung cancer screening expands, incidental findings rise, and artificial intelligence identifies more nodules requiring long-term surveillance.
- Clinical Impact: CyPath® Lung is positioned as a complementary tool to existing imaging and clinical assessment, offering objective, real-time information from the lung microenvironment through analysis of patient sputum—a method distinct from blood-based diagnostics.
-
Specialty-Specific Protocols: The published framework outlines protocols for pulmonology, primary care, and oncology practices, detailing how CyPath® Lung can be integrated into three primary care settings:
- Primary care practices managing incidentally discovered pulmonary nodules
- Pulmonary nodule programs and interventional pulmonology practices evaluating patients for biopsy
- Oncology practices conducting surveillance of cancer survivors
-
Strong Clinical Performance: CyPath® Lung has demonstrated impressive results in clinical trials, with:
- 92% sensitivity
- 87% specificity
- 88% accuracy
- 99% negative predictive value (NPV) for detecting lung cancer in high-risk patients with small, indeterminate nodules (<20mm)
- Commercial Experience: Drawing on three years of commercial use, the white paper provides clinical case studies that illustrate CyPath® Lung’s utility in clarifying cases where imaging and predictive models were inconclusive.
- Marketed as LDT: CyPath® Lung is marketed as a Laboratory Developed Test (LDT) and is not intended for use as a sole diagnostic tool, but as a supplement to other clinical assessments.
- Advantage Over Blood-Based Tests: The technology analyzes direct sputum samples, providing unique local insights from the lung microenvironment, which cannot be matched by blood-based diagnostics.
Key Issues for Shareholders and Potential Share Price Impact
- Growth Opportunity: The publication of a practical framework for integrating CyPath® Lung across multiple specialties could accelerate physician adoption and significantly expand the test’s addressable market.
- Rising Demand: The increase in lung cancer screening and incidental pulmonary nodule findings, spurred by broader use of imaging and AI, is likely to drive demand for advanced diagnostic tools like CyPath® Lung.
- Competitive Positioning: The report highlights CyPath® Lung’s advantages over blood-based diagnostics, which may provide a competitive edge as the market for noninvasive lung cancer testing grows.
- Revenue Expansion Potential: Expansion to primary care and oncology practices, in addition to pulmonology, could result in higher test volume and revenue growth.
- Regulatory and Market Risks: Investors should note the forward-looking statements regarding physician adoption, increased screening, and competitive threats from alternative technologies. The company warns that failure to achieve broad adoption or the success of competing diagnostics could materially impact future results.
- Validation and Clinical Acceptance: The inclusion of real-world case studies and strong clinical trial data in the white paper may help drive acceptance among clinicians and payors, further supporting commercialization efforts.
- Share Price Sensitivity: Successful adoption across a wider clinical base and validation of CyPath® Lung’s clinical utility could serve as significant catalysts for share price appreciation.
About bioAffinity Technologies and CyPath® Lung
bioAffinity Technologies, Inc. is focused on noninvasive early-stage cancer diagnostics and broad-spectrum cancer treatments. Its first product, CyPath® Lung, uses advanced flow cytometry and artificial intelligence to identify malignant cells in sputum samples from high-risk patients. The product is marketed by subsidiary Precision Pathology Laboratory Services under CLIA oversight.
Investor Contact
bioAffinity Technologies
Julie Anne Overton, Director of Communications
[email protected]
Disclaimer
This article is intended for informational purposes only and does not constitute investment advice or an offer to buy or sell securities. Forward-looking statements are subject to risks and uncertainties, and actual results may differ materially from those projected. Investors should review all relevant SEC filings and consult with their financial advisors before making investment decisions.
